Skip to main content
Erschienen in: European Journal of Epidemiology 1/2024

31.10.2023 | NEURO-EPIDEMIOLOGY

Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism

verfasst von: Sophie Lefèvre-Arbogast, Catherine Helmer, Claudine Berr, Stéphanie Debette, Cécilia Samieri

Erschienen in: European Journal of Epidemiology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Higher coffee consumption has been associated with reduced dementia risk, yet with inconsistencies across studies. CYP1A2 polymorphisms, which affects caffeine metabolism, may modulate the association between coffee and the risk of dementia and Alzheimer’s disease (AD). We included 5964 participants of the Three-City Study (mean age 74 years-old), free of dementia at baseline when they reported their daily coffee consumption, with available genome-wide genotyping and followed for dementia over a median of 9.0 (range 0.8–18.7) years. In Cox proportional-hazards models, the relationship between coffee consumption and dementia risk was modified by CYP1A2 polymorphism at rs762551 (p for interaction = 0.034). In multivariable-adjusted models, coffee intake was linearly associated with a decreased risk of dementia among carriers of the C allele only (“slower caffeine metabolizers”; HR for 1-cup increased [95% CI] 0.90 [0.83–0.97]), while in non-carriers (“faster caffeine metabolizers”), there was no significant association but a J-shaped trend toward a decrease in dementia risk up to 3 cups/day and increased risk beyond. Thus, compared to null intake, drinking ≥ 4 cups of coffee daily was associated with a reduced dementia risk in slower but not faster metabolizers (HR [95% CI] for ≥ 4 vs. 0 cup/day = 0.45 [0.25–0.80] and 1.32 [0.89–1.96], respectively). Results were similar when studying AD and another CYP1A2 candidate polymorphism (rs2472304), but no interaction was found with CYP1A2 rs2472297 or rs2470893. In this cohort, a linear association of coffee intake to lower dementia risk was apparent only among carriers of CYP1A2 polymorphisms predisposing to slower caffeine metabolism.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J Alzheimer’s Dis. 2009;17:661–80.CrossRef Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-β levels in aged Alzheimer’s disease mice. J Alzheimer’s Dis. 2009;17:661–80.CrossRef
2.
Zurück zum Zitat Wu L, Sun D, He Y. Coffee intake and the incident risk of cognitive disorders: a dose–response meta-analysis of nine prospective cohort studies. Clin Nutr. 2017;36:730–6.CrossRefPubMed Wu L, Sun D, He Y. Coffee intake and the incident risk of cognitive disorders: a dose–response meta-analysis of nine prospective cohort studies. Clin Nutr. 2017;36:730–6.CrossRefPubMed
3.
Zurück zum Zitat Larsson SC, Orsini N. Coffee consumption and risk of dementia and Alzheimer’s disease: a dose-response meta-analysis of prospective studies. Nutrients. 2018;10: 1501.CrossRefPubMedPubMedCentral Larsson SC, Orsini N. Coffee consumption and risk of dementia and Alzheimer’s disease: a dose-response meta-analysis of prospective studies. Nutrients. 2018;10: 1501.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163 C > A polymorphism. Eur J Clin Pharmacol. 2010;66:697–703.CrossRefPubMed Djordjevic N, Ghotbi R, Jankovic S, Aklillu E. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163 C > A polymorphism. Eur J Clin Pharmacol. 2010;66:697–703.CrossRefPubMed
5.
Zurück zum Zitat Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol. 2011;18:756–65.CrossRefPubMedPubMedCentral Popat RA, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, et al. Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease. Eur J Neurol. 2011;18:756–65.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Cornelis MC, Bennett DA, Weintraub S, Schneider JA, Morris MC. Caffeine consumption and dementia: are lewy bodies the link? Ann Neurol. 2022;91:834–46.CrossRefPubMedPubMedCentral Cornelis MC, Bennett DA, Weintraub S, Schneider JA, Morris MC. Caffeine consumption and dementia: are lewy bodies the link? Ann Neurol. 2022;91:834–46.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet. 2016;25:5472–82.PubMed Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet. 2016;25:5472–82.PubMed
9.
Zurück zum Zitat Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017;359.CrossRefPubMedPubMedCentral Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017;359.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Larsson SC, Woolf B, Gill D. Plasma caffeine levels and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomization study. Nutrients. 2022;14: 1697.CrossRefPubMedPubMedCentral Larsson SC, Woolf B, Gill D. Plasma caffeine levels and risk of Alzheimer’s disease and Parkinson’s disease: Mendelian randomization study. Nutrients. 2022;14: 1697.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Nordestgaard AT, Nordestgaard BG, Frikke-Schmidt R, Juul Rasmussen I, Bojesen SE. Self-reported and genetically predicted coffee consumption and smoking in dementia: a Mendelian randomization study. Atherosclerosis. 2022;348:36–43.CrossRefPubMed Nordestgaard AT, Nordestgaard BG, Frikke-Schmidt R, Juul Rasmussen I, Bojesen SE. Self-reported and genetically predicted coffee consumption and smoking in dementia: a Mendelian randomization study. Atherosclerosis. 2022;348:36–43.CrossRefPubMed
12.
Zurück zum Zitat Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Jung G, et al. Coffee intake and decreased amyloid pathology in human brain. Transl Psychiatry. 2019;9:1–10.CrossRef Kim JW, Byun MS, Yi D, Lee JH, Jeon SY, Jung G, et al. Coffee intake and decreased amyloid pathology in human brain. Transl Psychiatry. 2019;9:1–10.CrossRef
13.
Zurück zum Zitat Pham K, Mulugeta A, Zhou A, O’Brien JT, Llewellyn DJ, Hyppönen E. High coffee consumption, brain volume and risk of dementia and stroke. Nutr Neurosci. 2022;25:2111–22.CrossRefPubMed Pham K, Mulugeta A, Zhou A, O’Brien JT, Llewellyn DJ, Hyppönen E. High coffee consumption, brain volume and risk of dementia and stroke. Nutr Neurosci. 2022;25:2111–22.CrossRefPubMed
Metadaten
Titel
Habitual coffee consumption and risk of dementia in older persons: modulation by CYP1A2 polymorphism
verfasst von
Sophie Lefèvre-Arbogast
Catherine Helmer
Claudine Berr
Stéphanie Debette
Cécilia Samieri
Publikationsdatum
31.10.2023
Verlag
Springer Netherlands
Erschienen in
European Journal of Epidemiology / Ausgabe 1/2024
Print ISSN: 0393-2990
Elektronische ISSN: 1573-7284
DOI
https://doi.org/10.1007/s10654-023-01060-x

Weitere Artikel der Ausgabe 1/2024

European Journal of Epidemiology 1/2024 Zur Ausgabe